Cancer has become a major public health threat and is responsible for over 20% of all deaths worldwide. In medical science, the treatment of cancer has always been a major challenge, with conventional methods such as surgery, chemotherapy, and radiotherapy forming the backbone of therapeutic strategies. Although these methods are central to the management and control of cancer, they are subject to significant limitations. The effectiveness of chemotherapy and radiotherapy is often hampered by the inherent resistance developed by cancer cells. Despite significant spending on cancer research and drug development, the proportion of approved therapies in oncology is low compared to various other indications, so new approaches are needed. An attractive approach in this area is drug repurposing, which involves finding new uses for known therapeutic drugs outside their original medical indications. The cooccurrence of mental health problems and cancer has received particular attention. In this context, the potential role of antipsychotic drugs in anticancer therapy represents a promising and interesting area of research. In recent years, research studies have found that antipsychotics reduced the incidence of certain types of cancer in patients with schizophrenia, suggesting that they may have anticancer potential. Antipsychotics, traditionally used to treat psychotic disorders, have shown a complex interplay of molecular mechanisms that go beyond neurotransmission theory. Some of these mechanisms intriguingly overlap with cancer pathways. This chapter explores the unconventional anticancer properties of antipsychotic drugs, focusing on their potential to modulate key molecular mechanisms overlapping with cancer pathways. Research has suggested that antipsychotics might offer new therapeutic avenues by affecting immune modulation, cell signalling, and apoptosis pathways. The chapter delves into preclinical studies on antipsychotics’ effects on cancers, highlighting their immune system impact, potential to integrate into future treatment protocols, and the necessity for further exploration of their anticancer capabilities.